Evidence map›Paper›PMID 24831519›Full record

ArticlePloS one2014

Gene expression profiling in peripheral blood mononuclear cells of patients with common variable immunodeficiency: modulation of adaptive immune response following intravenous immunoglobulin therapy.

Marzia Dolcino, Giuseppe Patuzzo, Alessandro Barbieri, Elisa Tinazzi, Monica Rizzi, Ruggero Beri, Giuseppe Argentino, Andrea Ottria, Claudio Lunardi, Antonio Puccetti

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Chemokine receptor-4 targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2020
    Trial
  2. Article
  3. Article
  4. Immune Response toJournal of immunology research · 2018
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Marzia DolcinoDepartment of Immunology, Institute Giannina Gaslini, Genova, Italy.
Giuseppe PatuzzoDepartment of Medicine, University of Verona, Verona, Italy.
Alessandro BarbieriDepartment of Medicine, University of Verona, Verona, Italy.
Elisa TinazziDepartment of Medicine, University of Verona, Verona, Italy.
Monica RizziDepartment of Medicine, University of Verona, Verona, Italy.
Ruggero BeriDepartment of Medicine, University of Verona, Verona, Italy.
Giuseppe ArgentinoDepartment of Medicine, University of Verona, Verona, Italy.
Andrea OttriaDepartment of Experimental Medicine, University of Genova, Genova, Italy.
Claudio LunardiDepartment of Medicine, University of Verona, Verona, Italy.
Antonio PuccettiDepartment of Immunology, Institute Giannina Gaslini, Genova, Italy; Department of Experimental Medicine, University of Genova, Genova, Italy.
University of Verona · ITUniversity of Genoa · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegular intravenous immunoglobulin treatment is used to replace antibody deficiency in primary immunodeficiency diseases; however the therapeutic effect seems to be related not only to antibody replacement but also to an active role in the modulation of the immune response. Common variable immunodeficiency is the most frequent primary immunodeficiency seen in clinical practice.

methodsWe have studied the effect of intravenous immunoglobulin replacement in patients with common variable immunodeficiency by evaluating the gene-expression profiles from Affimetrix HG-U133A. Some of the gene array results were validated by real time RT-PCR and by the measurement of circulating cytokines and chemokines by ELISA. Moreover we performed FACS analysis of blood mononuclear cells from the patients enrolled in the study.

resultsA series of genes involved in innate and acquired immune responses were markedly up- or down-modulated before therapy. Such genes included CD14, CD36, LEPR, IRF-5, RGS-1, CD38, TNFRSF25, IL-4, CXCR4, CCR3, IL-8. Most of these modulated genes showed an expression similar to that of normal controls after immunoglobulin replacement. Real time RT-PCR of selected genes and serum levels of IL-4, CXCR4 before and after therapy changed accordingly to gene array results. Interestingly, serum levels of IL-8 remained unchanged, as the corresponding gene, before and after treatment. FACS analysis showed a marked decrease of CD8+T cells and an increase of CD4+T cells following treatment. Moreover we observed a marked increase of CD23⁻CD27⁻IgM⁻IgG⁻ B cells (centrocytes).

conclusionsOur results are in accordance with previous reports and provide further support to the hypothesis that the benefits of intravenous immunoglobulin therapy are not only related to antibody replacement but also to its ability to modulate the immune response in common variable immunodeficiency.

Indexed as

Adaptive ImmunityGene Expression ProfilingAdultCell SeparationCommon Variable ImmunodeficiencyEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGene ExpressionHumansImmunoglobulins, IntravenousLeukocytes, MononuclearMaleMiddle AgedOligonucleotide Array Sequence AnalysisRNA, ComplementaryImmunoglobulins, IntravenousRNA, Complementary

Identifiers

PMID24831519
PMCPMC4022614
OpenAlexW2010080293

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.